Peptides covering CCR5 extracellular regions and Ig reactivity obtained with LTNP samples
. | CCR5 external domain sequence . | Ig reactivity . | . | . | . | . | . | . | . | . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptide . | . | 4 . | 11 . | 20 . | 21 . | 22 . | 152 . | 110 . | 173 . | NY4 . | NY6 . | NY9 . | NY10 . | |||||||||||
| 1 | MDYQVSSPIYDINYYTSEPC | — | — | — | — | — | — | — | — | ND | ND | ND | ND | |||||||||||
| 3 | cYAAAQWDFGNTMCQ | 5.2 | 5.4 | 4 | 7.4 | 5.9 | 6.8 | 8 | 7.7 | + | + | + | + | |||||||||||
| 4 | CSSHFPYSQYQFWKNFQTLKc | — | — | — | — | — | — | — | — | ND | ND | ND | ND | |||||||||||
. | CCR5 external domain sequence . | Ig reactivity . | . | . | . | . | . | . | . | . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptide . | . | 4 . | 11 . | 20 . | 21 . | 22 . | 152 . | 110 . | 173 . | NY4 . | NY6 . | NY9 . | NY10 . | |||||||||||
| 1 | MDYQVSSPIYDINYYTSEPC | — | — | — | — | — | — | — | — | ND | ND | ND | ND | |||||||||||
| 3 | cYAAAQWDFGNTMCQ | 5.2 | 5.4 | 4 | 7.4 | 5.9 | 6.8 | 8 | 7.7 | + | + | + | + | |||||||||||
| 4 | CSSHFPYSQYQFWKNFQTLKc | — | — | — | — | — | — | — | — | ND | ND | ND | ND | |||||||||||
A specific concentration of human Igs from the 12 LTNPs was obtained only when peptide 3 was used. CCR5 specific antibodies from some LTNP were quantified and expressed as percentage of total serum Igs. Ig reactivity was negative in all samples for peptide 2 with a CCR5 external domain sequence of YYTSEPCQKINVKQIAARLLP and for peptide 5 with a CCR5 external domain sequence of FQEFFGLNNCSSSNR. An unrelated peptide, with sequence of VQGEESNDK, was used as negative control.
ND indicates not done; —, Ig reactivity was negative; and +, that Ig reactivity was positive but not quantified.